The Differentiation
In the last 12 months, CymaBay (CBAY) has potentially established seladelpar, its lead drug asset, as an improved second-line therapy for PBC based on the 52-week Phase 2b data. As a small cap ($849M) biopharma, CymaBay is making liver therapeutic waves with seladelpar, a new generation PPAR-? agonist currently in clinical trials for PBC, PSC and NASH, the focus of this article.
The pleiotropic clinical qualities of seladelpar at improving dyslipidemia that should trigger liver fat reduction in NASH are summarized. Based on my research, I foresee seladelpar ultimately exhibiting clinical